MedCity News

APRIL 12, 2024

Kaiser Permanente’s new Food is Medicine Center of Excellence will “combine clinical services, research, education and community engagement,” according to the organization. The post Kaiser Permanente Unveils Food is Medicine Center of Excellence appeared first on MedCity News.

Food 293

Food Medicine Education 293

MedCity News

MAY 9, 2024

One irony of personalized or precision medicine (PM) is that it aims, against the advice of Hippocrates and Osler, to treat the disease, not the patient. The post Why Personalized Medicine Should Not Be Too Personalized appeared first on MedCity News.

Medicine 284

Medicine Patients Biopharma 284

MedCity News

AUGUST 15, 2024

The post Good Measures, Point32Health Launch Food as Medicine Partnership appeared first on MedCity News. Through a new partnership with Good Measures, some Point32Health members have gained access to nutrition counseling, food tracking and other services.

Food 300

Food Medicine 300

MedCity News

OCTOBER 2, 2024

Lilly Medicine Foundry will research new ways to manufacture medicines. Medicine Foundry to Foster Innovations in Drug Manufacturing appeared first on MedCity News. The post Eli Lilly Plans $4.5B

Manufacturing 299

Manufacturing Medicine Biopharma Pharma 299

MedCity News

AUGUST 5, 2024

During a webinar hosted by PitchBook, healthcare experts shared that the food-as-medicine space will likely see consolidation in the future, as well as advancements in technology and reimbursement. The post What Does the Future of the Food-As-Medicine Market Look Like? appeared first on MedCity News.

Food 274

Food Medicine Marketing Healthcare 274

MedCity News

SEPTEMBER 27, 2022

Prime Medicine likens its gene-editing technology to a word processor that searches for the correct place in the genome to make an edit, replacing or repairing a wide variety of target DNA. The preclinical biotech is now spelling out its future plans with the letters I-P-O.

Medicine 322

Medicine Biopharma Pharma 322

MedCity News

APRIL 25, 2024

The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics.

Medicine 335

Medicine Pharmaceutical Biopharma Pharma 335

MedCity News

JANUARY 28, 2024

As the food as medicine movement grows, some payers and healthcare organizations are carving out specific roles and teams dedicated to food and nutrition. Doing so can be beneficial considering the significant impact diet can have on health outcomes.

Food 346

Food Medicine Healthcare Healthcare 346

MedCity News

AUGUST 8, 2024

The post Blue Cross Blue Shield of Tennessee Taps FarmboxRx for Food as Medicine Initiative appeared first on MedCity News. Through a new partnership with FarmboxRx, Blue Cross Blue Shield of Tennessee members will receive healthy food deliveries after they complete preventive health screenings, like a diabetic eye exam.

Food 293

Food Medicine 293

MedCity News

NOVEMBER 14, 2024

Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF. The deal comes one day after BioNTech announced an $800 million acquisition that gives it full rights to a molecule in this hot class of cancer drug candidates.

Medicine 301

Medicine Biopharma Pharma 301

MedCity News

NOVEMBER 10, 2023

As the industry moves towards more personalized medicine, pharmacogenomics could play a key role in keeping patients healthier longer and in getting them viable treatments for their unique genetic profile.

Medicine 284

Medicine Patients Biopharma 284

MedCity News

JANUARY 6, 2025

Orbis Medicines Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.

Medicine 288

Medicine Medical Biopharma 288

MedCity News

SEPTEMBER 30, 2024

Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The post Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb appeared first on MedCity News.

Medicine 283

Medicine Pharma Biopharma 283

MedCity News

JULY 15, 2024

Revolution Medicines drug RMC-6236 increased progression-free survival in patients with advanced cases of pancreatic ductal adenocarcinoma. The post Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug appeared first on MedCity News.

Medicine 273

Medicine Patients Biopharma 273

MedCity News

MARCH 26, 2024

During a panel discussion on GLP-1s at the Abarca Forward conference, one health executive stressed the importance of a food-as-medicine approach.

Food 293

Food Medicine Healthcare Healthcare 293

MedCity News

APRIL 11, 2023

Culturally competent behavioral health provider ReKlame Health is rolling out an in-home program for addiction medicine care in New York City.

Medicine 284

Medicine Patients 284

MedCity News

MAY 17, 2024

The post The Lure of Specialty Medicine Pulls Nurse Practitioners From Primary Care appeared first on MedCity News. This development worries some people who track the health workforce, because current trends suggest primary care, soon might not be able to rely on them to mitigate the physician shortage.

Medicine 293

Medicine Physicians 293

Fierce Pharma

DECEMBER 12, 2023

Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S.

Medicine 331

Medicine Doctors Government Patients 331

MedCity News

NOVEMBER 10, 2024

By fostering collaboration and seamless data integration into healthcare systems, the industry is laying the groundwork for a future in which “personalized medicine” is so commonplace within clinical practice that we will just start calling it “medicine.”

Patients 306

Patients Medicine Healthcare Healthcare 306

MedCity News

OCTOBER 22, 2024

Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.

Medicine 283

Medicine Biopharma Pharma 283

MedCity News

MAY 10, 2023

Medical Affairs plays a critical role when it comes to driving adherence to evidence-based medicine (EBM) – the principle that clinical decisions should be informed by the best available scientific evidence, along with clinical experience and patient preference.

Medicine 301

Medicine Medical Patients Biopharma 301

MedCity News

DECEMBER 18, 2023

The financing will be used to develop and scale its food-as-medicine programs, including for diabetes and high-risk pregnancies. Season Health has secured a $7 million investment from Inception Health and Ziegler Link-age Fund.

Food 272

Food Medicine 272

MedCity News

MARCH 4, 2024

Food-as-medicine executives are none too thrilled about his comments — they argue that the remarks underscore the dire need to increase public education about affordable, healthy meal planning. Kellogg CEO Gary Pilnick recently encouraged families struggling to put food on the table to turn to cereal as their go-to dinner option.

Food 313

Food Medicine Education 313

MedCity News

FEBRUARY 29, 2024

Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.

Medicine 284

Medicine Biopharma Pharma 284

MedCity News

JANUARY 10, 2025

Ouro Medicines drugs deplete disease-driving immune cells, allowing the immune system to reset with nave cells that dont attack the body. Monograph Capital founded the startup in partnership with GSK. The post Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System appeared first on MedCity News.

Medicine 259

Medicine Biopharma Pharma 259

MedCity News

OCTOBER 23, 2023

For example, all models tried to justify race-based medicine when asked questions about calculating patients’ kidney function and lung capacity — two areas where race-based medicine practices used to be common but have since been scientifically refuted.

Medicine 284

Medicine Patients Healthcare Healthcare 284

MedCity News

APRIL 26, 2023

ARCH Venture Partners-backed Orbital Therapeutics’ is researching next-generation RNA medicines that offer advantages over currently available therapies. The startup’s three areas of focus are vaccines, protein replacement, and immunomodulation.

Medicine 301

Medicine Biopharma Pharma 301

MedCity News

MAY 13, 2024

The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News. In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management.

Prescription 301

Prescription Medicine Pharma Biopharma 301

MedCity News

MAY 30, 2023

Employers have a responsibility to support the food as medicine movement and help employees who are food insecure, said Jay Bhatt, managing director of Deloitte Services and managing director of the Center for Health Solutions and Health Equity Institute. He made these comments last week at the MedCity INVEST conference in Chicago.

Food 274

Food Medicine Management 274

MedCity News

NOVEMBER 8, 2024

Use of this ingredient in cold and allergy medicines grew after a federal law required that pseudoephedrine-containing products be kept behind pharmacy counters. The FDA has proposed removing oral phenylephrine from its guidelines for over-the-counter drugs due to inefficacy as a decongestant.

FDA 300

FDA Marketing Medicine Biopharma 300

MedCity News

DECEMBER 22, 2024

The new approval gives the Eli Lilly medicine the opportunity to become a blockbuster seller in yet another indication. Zepbounds clinical tests in obstructive sleep apnea showed improvement in breathing disruptions that were accompanied by reductions in body weight.

FDA 281

FDA Medicine Biopharma Pharma 281

MedCity News

NOVEMBER 7, 2023

Baylor Medicine teamed up with Luna to launch a program expanding access to in-home physical therapy for patients in the Houston area. Luna, a provider of in-home physical therapy, has similar partnerships with more than two dozen health systems.

Medicine 284

Medicine Marketing Patients Healthcare 284

PharmaVoice

MAY 7, 2024

The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.”

Medicine 277

Medicine 277

MedCity News

JANUARY 8, 2025

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO markets return to normal levels.

Biopharma 306

Biopharma Medicine Marketing FDA 306

MedCity News

FEBRUARY 2, 2025

Investors showed appetite for Metseras IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.

Medicine 292

Medicine Biopharma Pharma 292

Fierce Pharma

DECEMBER 17, 2024

| After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.

Medicine 272

Medicine Patients 272

Fierce Pharma

FEBRUARY 22, 2024

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 263

Medicine Pharmaceutical 263